萬東醫療(600055.SH)上半年淨利潤升4.20%至4433.98萬元
格隆匯8月22日丨萬東醫療(600055.SH)發佈2019年半年度報告,實現營業收入3.78億元,同比減少0.61%;歸屬於上市公司股東的淨利潤4433.98萬元,同比增長4.20%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3928.85萬元,同比增長7.67%;基本每股收益0.082元。
報告期內,萬里雲線上業務持續快速增長,日均閲片量穩定在5萬張以上;新建3家第三方影像中心,線下業務收入已佔萬里雲營收的50%左右;完善建設專業化雲膠片、雲存儲、雲服務平台;肺部CT、健康肺、骨關節等人工AI閲片持續開展規模化試用。萬里雲業務基本成熟,經營持續增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.